Digest Network Come funziona
Network
/
Società
Bl
Non verificato

BlossomHill Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaOncologiaSalute

3 comunicati stampa

Guarda tutti i comunicati
03/04/2025
Eventi
Industria
Biotecnologia
Farmaceutica
Salute
Oncologia
BlossomHill Therapeutics to Present the Design and Discovery of BH-30643, the Company’s OMNI-EGFR™ Inhibitor, at the 2025 AACR Annual Meeting
Fonte
BlossomHill Therapeutics, Inc.
Emittente
Business Wire
1.00
0
22/01/2025
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
BlossomHill Therapeutics Doses Patients in the First Cohort of the Phase 1/2 SOLARA Clinical Trial of BH-30643 for EGFR- and HER2-Mutated Non-Small Cell Lung Cancer
Fonte
BlossomHill Therapeutics, Inc.
Emittente
Business Wire
1.00
0
06/01/2025
Mercato del lavoro
Oncologia
Salute
Scienza
Farmaceutica
Biotecnologia
BlossomHill Therapeutics Appoints Geoff Oxnard, M.D., as Chief Medical Officer and Executive Vice President
Fonte
BlossomHill Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0